Transgene SA TNG
EURONEXT · France · Health Technology
€0.7140-0.01 (-1.11%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Strasbourg, France, October 1, 2026, 5:45 pm CET — Transgene (Euronext Paris: TNG), a biotech company developing myvac®, an individualized neoantigen therapeutic vaccines (INTV) platform designed to prevent cancer recurrence together with a portfolio of virus-based candidates, today announced that its management team will meet institutional investors during the upcoming edition of Investor Access Event (by Investor Access), on October 6, 2026, in Paris. Organized by Investor Access, these events
2026 Half-Year Results and Business Update myvac® – Expanding potential across solid tumors through viral vector, AI driven neoantigen selection, and scalable cell-line manufacturing TG4050 – First Individualized Neoantigen Therapeutic Vaccine (INTV) from the myvac® platform advancing in resected HNSCC1 Randomized Phase 1 data published in Nature Communications; Sustained 100% disease-free survival (DFS) after more than 3 years of follow-up, showing durable clinical outcomes and potential to pre
Strasbourg (France), Berlin (Germany), September 8, 2026, 7:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading contract development and manufacturing organization (CDMO) in biologics, vaccines and viral vectors, today announce that the companies have broadened the scope of their existing collaboration. Transgene’s additional license agreement for ProBioGen’s AGE1.CR.pIX® sus
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.